Clinical Research Directory
Browse clinical research sites, groups, and studies.
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
Sponsor: Kupando GmbH
Summary
The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
21
Start Date
2026-07-03
Completion Date
2028-12
Last Updated
2026-08-12
Healthy Volunteers
No
Conditions
Interventions
KUP-101A
Intravenous infusion of KUP-101A
Locations (3)
Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Dermatologie und Allergologie
Munich, Bavaria, Germany
Universitätsklinikum Würzburg
Würzburg, Bavaria, Germany
Fachklinik Hornheide
Münster, North Rhine-Westphalia, Germany